Expertise in
14
conditions

Dr. Youn-hee H. Kim

Dermatology
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
14
conditions
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 

Overview

Youn-hee Kim is a Dermatologist practicing medicine in Palo Alto, California.

Dr. Kim is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Mycosis Fungoides, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Sezary Syndrome.

She is actively involved in clinical research, co-authoring 146 peer reviewed articles and participating in 8 clinical trials. Dr. Kim is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in CA

Hospital Affiliations

Stanford Health Care

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Santa Clara Family Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 13 Less Insurance Carriers -

Locations

Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
Enrollment Status: Recruiting
Publish Date: October 22, 2025
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
A Phase II Trial of MK-3475 (Pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated Mycosis Fungoides and Sezary Syndrome (Treatment Group 1) and in Patients With Advanced Synovial Sarcoma (Treatment Group 2)
Enrollment Status: Completed
Publish Date: October 25, 2023
Intervention Type: Other, Biological
Study Drugs: Interferon Gamma-1b, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Anti-Thymocyte Globulin, Cyclosporine
Study Phase: Phase 2
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

146 Total Publications

Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy.
Dissecting Immune Determinants in Lesional Skin of Cutaneous T-Cell Lymphoma During Mogamulizumab Therapy.
Journal: Cancers
Published: May 13, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral required
Before you request

Stanford University Medical Center

450 Broadway St, 
Redwood City, CA 
 (3.7 miles away)
650-723-6316
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. David Fiorentino, MD is a Dermatologist in Redwood City, CA and has over 24 years of experience in the medical field. He graduated from Stanford University in 1998. He is affiliated with Stanford Health Care. Dr. Fiorentino is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Dermatomyositis, Systemic Sclerosis (SSc), Scleroderma, and Calcinosis. Dr. Fiorentino is board certified in Board Certification: American Board Of Dermatology, Dermatology (2002). Dr. Fiorentino is currently accepting new patients.

Expertise in
97
conditions
Expertise in
97
conditions
Referral may be required
Before you request

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (1.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kerri Rieger is a Dermatologist practicing medicine in Palo Alto, California. Dr. Rieger is highly rated in 97 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Mycosis Fungoides, Melanoma, and Epidermolysis Bullosa with Pyloric Atresia. Dr. Rieger is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Stanford University Medical Center

450 Broadway St, 
Redwood City, CA 
 (3.7 miles away)
650-725-5272
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sumaira Aasi is a Dermatologist practicing medicine in Redwood City, California. Dr. Aasi is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Extramammary Paget Disease, and Melanoma. Dr. Aasi is currently accepting new patients.

Frequently Asked Questions about Dr. Youn-hee H. Kim

How do I make an appointment with Dr. Youn-hee H. Kim?

You can book an appointment with Dr. Youn-hee H. Kim by calling their office at 650-498-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Youn-hee H. Kim a top-rated expert for Mycosis Fungoides?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Youn-hee H. Kim is classified as an Elite expert for Mycosis Fungoides, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Youn-hee H. Kim specialize in?

While Dr. Youn-hee H. Kim is a Dermatology, they have specific expertise in Mycosis Fungoides, T-Cell Lymphoma, and Cutaneous T-Cell Lymphoma (CTCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Youn-hee H. Kim participate in research or clinical trials?

Yes. Dr. Youn-hee H. Kim has published 146 articles and abstracts on conditions like Mycosis Fungoides. You can view a list of Dr. Youn-hee H. Kim's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Youn-hee H. Kim accept my insurance?

Dr. Youn-hee H. Kim accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 650-498-6000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kim's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile